Eye Medication Monitoring for Myopia Dose and Receptor Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current devices and methods for measuring pupil size and accommodation fail to accurately determine the level of muscarinic receptor blockade and intra-ocular penetration/concentration of anti-muscarinic medications, which are crucial for optimizing myopia treatment regimes, as they only measure end results masked by complex feedback loops and do not account for variable factors like drug stability and melanin binding.
Innovation Solution
A system and method using an accommodation or accommodative convergence measurement device to estimate intra-ocular concentration by computing parameters like pupil diameter changes and comparing them with reference databases, allowing for optimal treatment regime determination based on receptor blockade and penetration levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If low dose atropine (0.01%) is used to minimize side effects, then pupil dilatation and accommodation paralysis are reduced, but the effectiveness in preventing myopia progression becomes uncertain due to variable intra-ocular penetration and receptor blockade
Solution Approach 1:
The system implements feedback by measuring pupil light response and accommodation response, then using these measurements to estimate the level of muscarinic receptor blockade and intra-ocular drug concentration. This feedback loop allows real-time monitoring of drug effectiveness and adjustment of treatment regime to maintain optimal therapeutic levels while minimizing side effects
Solution Approach 2:
The patent replaces direct measurement of drug concentration (which would require invasive sampling) with indirect optical and physiological measurements. By substituting mechanical/chemical measurement with optical pupillometry and accommodation response measurement, the system achieves non-invasive monitoring of receptor blockade levels
2Reliability
If standard dose atropine (0.5%-1.0%) is used to ensure effective myopia prevention, then receptoral blockade and intra-ocular concentration are maximized, but pupil dilatation and accommodation paralysis occur as harmful side effects
Solution Approach 1:
The system enables dynamic adjustment of atropine dosage based on individual patient response. By continuously monitoring pupil light response and accommodation response, the treatment regime can be optimized in real-time, transitioning from static fixed dosing to dynamic personalized dosing that adapts to each patient's intra-ocular penetration and receptor sensitivity
Solution Approach 2:
The patent changes the dosing parameters of atropine based on measured receptor blockade levels. By adjusting concentration and frequency of administration according to actual intra-ocular drug levels and receptor occupancy, the system achieves effective myopia prevention with minimized side effects through parameter optimization
3Reliability
If atropine is administered frequently or at higher concentrations to ensure therapeutic effectiveness, then intra-ocular concentration increases, but drug instability at physiological pH leads to loss of active drug over time
Solution Approach 1:
The system performs preliminary assessment of individual patient factors (iris pigmentation, intra-ocular penetration rate) before initiating treatment. By predicting the required dose based on these pre-measured parameters, the system optimizes the initial prescription to achieve therapeutic effectiveness while minimizing drug degradation and loss
4Ease of operation
If existing pupillometry and accommodation measurement devices are used, then pupil size and accommodation response can be measured, but the level of muscarinic receptor blockade and intra-ocular drug concentration cannot be accurately determined due to masking by feedback loops
Solution Approach 1:
The system introduces computational algorithms and reference databases as intermediaries between the raw measurements and the final estimation of receptor blockade. By using standardized protocols and comparing measurements against reference data, the system translates ordinary pupillometry and accommodation measurements into precise estimates of muscarinic receptor occupancy and intra-ocular drug concentration
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
A system for and method of monitoring/measuring the level of receptoral action/blockade and intra-ocular penetration/concentration of an eye medication and determining an optimal treatment regime based on the level of receptoral action/blockade and intra-ocular penetration/concentration of the eye medication.